Success Metrics

Completion Rate
0%(0/3)
Active Trials
1(25%)
Terminated
3(75%)

Phase Distribution

Ph phase_1
2
50%
Ph phase_2
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Terminated(3)

Detailed Status

Terminated3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

terminated375%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
terminatedphase_2

Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

NCT05464836
recruitingphase_1

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

NCT05774899
terminatedphase_1

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

NCT03422679
terminatedphase_2

CB-103 Plus NSAI In Luminal Advanced Breast Cancer

NCT04714619

Clinical Trials (4)

Showing 4 of 4 trials
NCT05464836Phase 2

Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

Terminated
NCT05774899Phase 1

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Recruiting
NCT03422679Phase 1

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Terminated
NCT04714619Phase 2

CB-103 Plus NSAI In Luminal Advanced Breast Cancer

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4